Literature DB >> 34541178

Teratoma Formation Assay for Assessing Pluripotency and Tumorigenicity of Pluripotent Stem Cells.

Shingo Miyawaki1,2,3, Yohei Okada2,4, Hideyuki Okano2, Kyoko Miura1,2.   

Abstract

Pluripotent stem cells such as induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) form teratomas when transplanted into immunodeficient mice. As teratomas contain all three germ layers (endoderm, mesoderm, ectoderm), teratoma formation assay is widely used as an index of pluripotency (Evans and Kaufman, 1981; Hentze et al., 2009 ; Gropp et al., 2012 ). On the other hand, teratoma-forming tumorigenicity also represents a major risk factor impeding potential clinical applications of pluripotent stem cells ( Miura et al., 2009 ; Okano et al., 2013 ). Recently, we reported that iPSCs derived from naked mole-rat lack teratoma-forming tumorigenicity when engrafted into the testes of non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice due to an ES cell-expressed Ras (ERAS) and Alternative reading frame (ARF)-dependent tumor-suppression mechanism specific to this species ( Miyawaki et al., 2016 ). Here, we describe a method for transplanting pluripotent stem cells into the testes of NOD/SCID mice to generate teratomas for assessing the pluripotency and tumorigenicity.
Copyright © 2017 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  NOD/SCID mice; Pluripotent stem cells; Teratoma; Testis; Tumorigenicity

Year:  2017        PMID: 34541178      PMCID: PMC8413610          DOI: 10.21769/BioProtoc.2518

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  12 in total

Review 1.  The blood-testis barrier and its implications for male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Pharmacol Rev       Date:  2011-10-28       Impact factor: 25.468

2.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

3.  Variation in the safety of induced pluripotent stem cell lines.

Authors:  Kyoko Miura; Yohei Okada; Takashi Aoi; Aki Okada; Kazutoshi Takahashi; Keisuke Okita; Masato Nakagawa; Michiyo Koyanagi; Koji Tanabe; Mari Ohnuki; Daisuke Ogawa; Eiji Ikeda; Hideyuki Okano; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2009-07-09       Impact factor: 54.908

Review 4.  Steps toward safe cell therapy using induced pluripotent stem cells.

Authors:  Hideyuki Okano; Masaya Nakamura; Kenji Yoshida; Yohei Okada; Osahiko Tsuji; Satoshi Nori; Eiji Ikeda; Shinya Yamanaka; Kyoko Miura
Journal:  Circ Res       Date:  2013-02-01       Impact factor: 17.367

5.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

6.  Generation of germline-competent induced pluripotent stem cells.

Authors:  Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

7.  Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.

Authors:  Alejandro Vazquez-Martin; Sílvia Cufi; Eugeni Lopez-Bonet; Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Begoña Martin-Castillo; Javier A Menendez
Journal:  Sci Rep       Date:  2012-12-12       Impact factor: 4.379

8.  Tumour resistance in induced pluripotent stem cells derived from naked mole-rats.

Authors:  Shingo Miyawaki; Yoshimi Kawamura; Yuki Oiwa; Atsushi Shimizu; Tsuyoshi Hachiya; Hidemasa Bono; Ikuko Koya; Yohei Okada; Tokuhiro Kimura; Yoshihiro Tsuchiya; Sadafumi Suzuki; Nobuyuki Onishi; Naoko Kuzumaki; Yumi Matsuzaki; Minoru Narita; Eiji Ikeda; Kazuo Okanoya; Ken-Ichiro Seino; Hideyuki Saya; Hideyuki Okano; Kyoko Miura
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

9.  Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives.

Authors:  Go Itakura; Soya Kawabata; Miki Ando; Yuichiro Nishiyama; Keiko Sugai; Masahiro Ozaki; Tsuyoshi Iida; Toshiki Ookubo; Kota Kojima; Rei Kashiwagi; Kaori Yasutake; Hiromitsu Nakauchi; Hiroyuki Miyoshi; Narihito Nagoshi; Jun Kohyama; Akio Iwanami; Morio Matsumoto; Masaya Nakamura; Hideyuki Okano
Journal:  Stem Cell Reports       Date:  2017-03-02       Impact factor: 7.765

10.  Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny.

Authors:  Michal Gropp; Vitali Shilo; Gilad Vainer; Miri Gov; Yaniv Gil; Hanita Khaner; Limor Matzrafi; Maria Idelson; Juri Kopolovic; Naomi B Zak; Benjamin E Reubinoff
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more
  1 in total

Review 1.  Principles and Protocols For Post-Cryopreservation Quality Evaluation of Stem Cells in Novel Biomedicine.

Authors:  Jingxian Xie; Marlene Davis Ekpo; Jian Xiao; Hongbin Zhao; Xiaoyong Bai; Yijie Liang; Guang Zhao; Dong Liu; Songwen Tan
Journal:  Front Pharmacol       Date:  2022-05-03       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.